Vicore trades at 7x lower val. vs US listed but worse Pliant

NordicGuy
VICO 23.05.2023 kl 09:17 584

Vicore is the most interesting opportunity in Swedish pharma.

It is the first drug that can cure IPF. Drug with much worth results sold in 21 for 3.5 bln USD. Vicore trades at 5% of that despite having the best ever seen results in the IPF. All anaylsts are very bullish:

For example Carnegie Research 22/5/23:

“We therefore argue that Vicore’s research hypothesis holds up, and that the new findings, confirming that C21 could become the first drug to restore the lung function in IPF, validate C21’s truly transformative potential.”

Full thesis is below:

https://fitinvestmentideas.com/2023/05/23/vicore-first-drug-that-cures-ipf-trading-at-1-7-of-its-peer-with-worse-results/
NordicGuy
25.05.2023 kl 13:55 322

REMINDER - Vicore webcast on AIR trial interim update

Data demonstrate sustained disease stabilization and increase in lung function in idiopathic pulmonary fibrosis (IPF) patients
C21 has the potential to transform the treatment of IPF and restore lung function

Webcast presentation & Q&A to be held on May 26, 2023, at 08:00 EST/14:00 CET
Register and submit questions: https://brrmedia.news/VICO_TU23


Following the compelling data presented at the 2023 ATS Congress, Vicore is proud to present the interim data analysis from the AIR trial with C21 in idiopathic pulmonary fibrosis (IPF). The results are based on a more advanced dataset, encompassing a comprehensive examination of the patient population and biomarkers. Additionally, the presentation will cover the future steps for the AIR trial and development plans.

Professor Toby Maher, from Keck School of Medicine at University of Southern California, will present data along with Carl-Johan Dalsgaard, CEO, and Rohit Batta, CMO of Vicore. The speakers will discuss:

C21 continues to be safe and well tolerated with no treatment-related serious adverse events
C21 continues to demonstrate long-term efficacy, at 36 weeks the average FVC had increased to +350 mL over baseline, which is +530 mL over the expected trajectory of untreated patients (n=19; p=0.001)
Vicore plans to progress clinical development of C21 through initiation of a phase 2b trial (ANDAS) and will conclude recruitment to the AIR trial
To read the full press release.

Webcast presentation details
C21 in IPF – Presentation of an advanced interim analysis
Date and time: Friday May 26, 2023 at 08:00 EST/14:00 CET
Register and submit questions: https://brrmedia.news/VICO_TU23

The webcast and presentation will be available after the webcast at: https://vicorepharma.com/investors/events-presentations/

About the AIR trial and interim results
The AIR trial[1], a multi-center, open label, single arm 24-week trial with a 12-week extension studying the safety and efficacy of the angiotensin II type 2 receptor agonist (ATRAG) C21 in patients with IPF, has now enrolled 51 patients. At the time of analysis, 27 patients had completed 24 weeks of treatment with an average increase in FVC of +50mL and a 3-visit average increase of +110 mL (p=0.007 versus the expected trajectory of untreated patients), and 19 patients had completed 36 weeks of treatment with an average increase in FVC of +350 mL and a 3-visit average increase of +220 mL (p=0.001 versus the expected trajectory of untreated patients). Out of the 19 patients that had completed 36 weeks of treatment, 17 presented an FVC value that was better than what would have been expected of an untreated population. The new dataset shows a stabilization of lung capacity already at week 6 and, in line with previous interim analysis, a subsequent increase of FVC from week 16 to 36. Now, with twice the number of patients versus the interim analysis announced in November 2022, the previously reported early stabilization followed by an increase in lung function is confirmed, suggesting that C21 has the potential to transform the treatment of IPF.

C21 continued to be safe and well tolerated with no treatment-related serious adverse events; there was a low rate of disease progression or worsening of cough and no gastrointestinal tolerability issues. 94% and 96% of patients at week 12 and 24, respectively, showed a positive benefit/risk, according to a joint benefit/risk assessment by the patients and principal investigator.

Recruitment to the AIR trial will be concluded to fully focus on the next step of development, the phase 2b ANDAS trial. Vicore has engaged world leading experts and patient advocacy organizations in its advisory committee to aid in the design and successful conduct of the trial.

Biography Toby Maher
Toby Maher is a Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, Los Angeles (USC). Dr Maher has spent the last 18 years specializing in the management of all forms of pulmonary fibrosis and orphan interstitial lung diseases (ILD). He previously ran the ILD unit at Royal Brompton Hospital. Since June 2020 he has been Director of ILD at Keck Medicine of USC. He remains Professor of Interstitial Lung Disease at Imperial College London and is British Lung Foundation Professor of Respiratory Medicine.